Patient characteristics, n (%)
| Age, median (range), year | 69.5 (48–77) |
| Gender | |
| Male | 12 (60) |
| Female | 8 (40) |
| Tumour type | |
| Lung | 11 (55) |
| Melanoma | 7 (35) |
| Renal | 1 (5) |
| Lymphoma | 1 (5) |
| Cancer therapy | |
| Anti-PD-1 | 18 (90) |
| Combination anti-CTLA-4/anti-PD-1 | 2 (10) |
| Pre-existing autoimmune disease | |
| No | 18 (90) |
| Yes (RA) | 2 (10) |
| Type of rheumatic irAE | |
| RA-like | 16 (80) |
| PMR-like | 2 (10) |
| PsA-like | 2 (10) |
| Type of bDMARD/tsDMARD used | |
| Anti-IL-6R | 13 (65) |
| Tocilizumab | 12 (57) |
| Sarilumab | 1 (5) |
| TNF inhibitors | 5 (25) |
| Etanercept | 2 (9.5) |
| Adalimumab | 2 (9.5) |
| Infliximab | 1 (5) |
| Others | 3 (15) |
| Anakinra | 1 (5) |
| Baricitinib | 1 (5) |
| Ustekinumab | 1 (5) |
| ICI discontinuation | |
| No | 3 (15) |
| Temporarily | 5 (25) |
| Permanently* | 12 (60) |
*For other irAE (n=2: colitis and pneumonitis).
bDMARD, biologic disease-modifying antirheumatic drug; CTLA-4, cytotoxic T-lymphocyte antigen 4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed cell death protein 1; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.